Neuropace, Inc. NPCE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 78.3%+1.1pp | 77.2%+0.5pp | 76.8%+1.0pp | 75.7%+0.9pp | 74.8%+0.9pp | |
| Operating margin | -16.8%-0.5pp | -16.3%+2.9pp | -19.2%+3.2pp | -22.4%+0.4pp | -22.9%+4.3pp | |
| Net margin | -21.7%-0.2pp | -21.5%+3.8pp | -25.3%+4.0pp | -29.3%+0.1pp | -29.4%+4.5pp | |
| EBITDA margin | -16.5%-0.5pp | -16%+2.9pp | -18.9%+3.2pp | -22.1%+0.4pp | -22.5%+4.2pp | |
| Free cash flow margin | -10.3%+1.5pp | -11.7%+5.7pp | -17.5%+1.1pp | -18.6%+3.0pp | -21.5%+1.3pp | |
| Returns | ||||||
| Return on equity | -111.4%+47.4pp | -158.7%+10.5pp | -169.3%+7.7pp | -176.9%-48.4pp | -128.5%+60.9pp | |
| Return on assets | -20.6%+0.8pp | -21.4%+2.1pp | -23.6%+2.3pp | -25.9%-2.1pp | -23.7%+3.1pp | |
| Return on invested capital | -24%0.0pp | -24.1%+2.6pp | -26.7%+2.0pp | -28.7%-2.0pp | -26.7%+3.7pp | |
| Efficiency | ||||||
| Asset turnover | 1×0.0× | 1×+0.1× | 0.9×0.0× | 0.9×+0.1× | 0.8×0.0× | |
| Inventory turnover | 1.4×-0.1× | 1.5×0.0× | 1.5×-0.1× | 1.6×-0.1× | 1.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.4×+0.1× | 5.3×+0.4× | 4.9×-0.6× | 5.5×-1.2× | 6.6×+1.3× | |
| Quick ratio | 4.3×0.0× | 4.3×+0.4× | 3.9×-0.6× | 4.5×-1.2× | 5.7×+1.2× | |
| Cash ratio | 1×-0.3× | 1.2×+0.2× | 1.1×-0.3× | 1.3×-0.5× | 1.8×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 4.9×+1.2× | 3.7×-0.1× | 3.8×+0.2× | 3.7×+0.7× | 3×-6.1× | |
| Debt-to-assets | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×-0.1× | |
| Interest coverage | -2.5×-0.3× | -2.2×+0.1× | -2.3×0.0× | -2.3×-0.1× | -2.2×+0.2× | |
| Per Share | ||||||
| Book value per share | $0.43-26.3% | $0.58+4.1% | $0.56-5.5% | $0.59-23.3% | $0.77+180% | |
| Valuation | ||||||
| Market capitalization | $557.77M+63.4% | $514.27M+50.8% | $341.07M-3.4% | $352.91M-11.8% | $400.16M+19.8% | |
| Enterprise value | $612.6M+58.1% | $563.29M+43.9% | $391.48M-2.5% | $401.45M-10.0% | $446.17M+13.3% | |
| Price / sales | 5.6×+1.6× | 5.1×+1.5× | 3.6×-0.4× | 4×-0.8× | 4.7×+0.6× | |
| Price / book | 38.6×+24.5× | 27×+8.6× | 18.4×+0.3× | 18.2×+1.7× | 16.5×-25.2× | |
| EV / sales | 6.2×+1.6× | 5.6×+1.5× | 4.1×-0.4× | 4.5×-0.8× | 5.3×+0.4× | |
| Free cash flow yield | -1.8%+3.5pp | -2.3%+2.6pp | -4.9%-0.2pp | -4.7%-0.1pp | -4.5%+0.9pp | |
| Earnings yield | -3.9%+3.4pp | -4.2%+2.9pp | -7%+0.3pp | -7.4%-1.2pp | -6.2%+1.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Neuropace, Inc.'s profit margins?
- Neuropace, Inc. (NPCE) runs a 78.3% gross margin and a -16.8% operating margin, with a -21.7% net margin.
- Where do Neuropace, Inc.'s ratios come from?
- Every ratio is computed from Neuropace, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
